Cidara Therapeutics, Danaher, argenex, Vertex Pharmaceuticals, and Abivax are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of...
MarketBeat·2d ago
More News
Abivax (NASDAQ:ABVX) Sets New 12-Month High - Still a Buy?
Abivax (NASDAQ:ABVX) Hits New 12-Month High - Should You Buy...
MarketBeat·3d ago
Biotech Stocks To Keep An Eye On - November 16th
Cidara Therapeutics, Danaher, Vertex Pharmaceuticals, argenex, and Abivax are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of...
MarketBeat·3d ago
Biotech Stocks To Consider - November 14th
Cidara Therapeutics, Danaher, argenex, Vertex Pharmaceuticals, Abivax, Moderna, and United Therapeutics are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...
MarketBeat·4d ago
Abivax (NASDAQ:ABVX) Sees Strong Trading Volume - Still a Buy?
Abivax (NASDAQ:ABVX) Sees Strong Trading Volume - Time to Buy...
MarketBeat·5d ago
Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's What You Should Know
Abivax SA Sponsored ADR (ABVX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·7d ago
Are Medical Stocks Lagging Abivax SA Sponsored ADR (ABVX) This Year?
Here is how Abivax SA Sponsored ADR (ABVX) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
Zacks·8d ago
Abivax (NASDAQ:ABVX) Sets New 52-Week High - Should You Buy?
Abivax (NASDAQ:ABVX) Reaches New 52-Week High - Here's Why...
MarketBeat·9d ago
Small-Cap Abivax Spikes 400% On Positive Late-Stage Ulcerative Colitis Drug Trial Results — Retail Buzz Builds Around Blockbuster Potential
The drug candidate demonstrated a placebo-adjusted remission rate of 19.3% in the first study and 13.4% in the second study.
Stocktwits·4mo ago
US-listed Abivax shares skyrocket on positive phase 3 data for colitis drug
Investing.com-- U.S.-listed shares of French biotech firm Abivax SA (EPA:ABVX) (NASDAQ:ABVX) skyrocketed in post-market trading on Tuesday after the company reported strong results from late-stage trials of its oral ulcerative colitis treatment, obefazimod.